Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

Reck, M.Ciuleanu, T. E.Pluzanski, A.Lee, J. S.Caro, R. BernabeLinardou, H.Burgers, J.Gallardo, C.Nishio, M.Peters, S.Paz-Ares, L. G.Hellmann, M. D.Borghaei, H.Ramalingam, S. S.O'Byrne, K.Hu, N.Bushong, J.Eccles, L.Grootendorst, D.Brahmer, J. R.2025-01-072025-01-072021-12-100923-7534https://hdl.handle.net/10668/27921enNivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1conference outputopen access10.1016/j.annonc.2021.10.1411569-8041http://www.annalsofoncology.org/article/S0923753421046779/pdf731051400125